| Revenue TTM | ₹851.48 CrOperating Income |
|---|---|
| Market Cap | ₹5,571.16 CrPharmaceuticals |
| PE Ratio | 23.56xSector: 48.93x |
| Promoter Holding | 63.62%Zero Pledge |
Key highlights
- Launch of 8 new products including Acharya Ji Arogyam Vati and Nirogyam Vati tablets
- Introduction of the Jod Xpert series featuring specialized oil, roll-on, and tablet formats
- New nutraceutical plant protein line launched for General, Men, and Women categories
- Expansion follows a strong Q1 FY27 where net profit rose 46.1% sequentially to ₹65.95 crore
- Company maintains an annual Return on Equity of 47.49% with zero promoter pledge
Diversified Product Suite for Domestic Wellness
Jeena Sikho Lifecare has introduced a multi-format product range aimed at consolidating its position in the domestic Ayurvedic space. The new launches include the Jod Xpert series, which provides a three-pronged approach to pain management through oil, roll-ons, and tablets. Furthermore, the company is tapping into the high-growth nutraceutical segment with a suite of plant-based proteins.
These proteins are specifically formulated for three distinct demographics—General, Men, and Women—and are available in Chocolate, Mango, and Coffee flavors. This diversification into functional foods reflects the company's strategy to expand beyond traditional Vati tablets into modern wellness categories.
Sustained Launch Momentum in Late 2026
The October 5 rollout follows a period of intense product development and launches by the company. In September 2026 alone, Jeena Sikho introduced several products including Acharya Ji's Amrit Tattava Vati and specialized formulations under the Narie Xpert and Porush Xpert brands. This trend continued from August, which saw the launch of nine products, including liquid Arishta formulations and headache relief patches.
By rapidly expanding its stock-keeping units, the company aims to leverage its existing distribution network of over 120 clinics and hospitals to drive higher consumer wallet share in the wellness segment.
Financial Performance and Sector Positioning
Financially, Jeena Sikho is operating with a robust margin profile, reporting a 41.03% operating profit margin for the quarter ended June 30, 2026. The company achieved a quarterly revenue of ₹224.4 crore, representing a 28.76% growth compared to the previous year. While the stock has faced technical pressure, characterized as a Falling Comet with a 42.84% decline over the past year, its valuation remains competitive at a P/E of 23.56x against a sector average of 48.93x.
The high Piotroski Score of 7 underscores the company's strong financial health and operational efficiency during this expansion phase.
Strategic Roadmap and Operational Targets
- Commercial operations of a new 160-plus bed hospital facility in Lucknow are scheduled to commence in December 2026
- Management has issued a minimum PAT guidance of ₹300 crore for the 2027 fiscal year
- The company is targeting a long-term network expansion of 7,000 to 10,000 operational hospital beds over the next three to five years
- Long-term guidance anticipates a 4x to 5x growth in PAT over a four-year horizon starting from mid-2026
- The company recently received in-principle approval for listing up to 6,50,000 equity shares under its ESOS 2024 scheme
| Date | Announcement | Amount |
|---|---|---|
| 21 Sep 2026 | Launch of two Ayurvedic products: Acharya Ji's Amrit Tattava Vati (60 Tablets) and Acharya Ji's Oja Amrit Vati (60 Tablets)Source: jeenasikho.com | – |
| 05 Sep 2026 | Launch of two Ayurvedic products: Acharya Ji's Jeevanodya Vati (60 Tablets) and Acharya Ji's Ojavardhan Vati (60 Tablets)Source: NSE filing | – |
| 02 Sep 2026 | Launch of six Ayurvedic products under Narie Xpert and Porush Xpert brands (granules, syrup, and tablets)Source: scanx.trade | – |
| 26 Aug 2026 | Launch of nine Ayurvedic products: eight Arishta liquid formulations (500 ml) and Headache Relief PatchSource: scanx.trade | – |
| 04 Aug 2026 | Launch of Ayurvedic product Amrit Dhara Drops (20 ml)Source: jeenasikho.com | – |
| 27 Jul 2026 | Launch of four Ayurvedic pain relief patches (Back Pain Relief Patch, Knee Pain Relief Patch, and Pain Relief Patches)Source: NSE filing | – |
What to watch next
- Commencement of commercial operations at the Lucknow hospital facility in December 2026
- Quarterly financial results for the period ending September 30, 2026
- Updates on the operationalization of 450 immediate-pipeline hospital beds
| Share price | ₹448.2 |
|---|---|
| Market capitalisation | ₹5,571.16 Cr |
| Revenue (annual) | ₹801.36 Cr |
| Net profit (annual) | ₹221.85 Cr |
| Revenue (latest quarter) | ₹224.40 Cr+4.11% vs previous quarter |
| Net profit (latest quarter) | ₹65.95 Cr+46.12% vs previous quarter |
| P/E (TTM) | 23.56×Sector 48.93× |
| Promoter holding | 63.62%0.00% QoQ |
| FII holding | 4.78%Current quarter |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
Exchange filing by Jeena Sikho Lifecare Limited announcing the launch of eight new Ayurvedic and nutraceutical products. Market figures from a third-party data provider.
Track Jeena Sikho Lifecare live
Get the next Jeena Sikho Lifecare filing on Telegram seconds after it lands. 15 days free.
